Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
October 5, 2018
Recipient of Prize Paper Award from the Society for Assisted Reproductive Technology (SART) Geneva, Switzerland and Boston, MA – October 5, 2018– ObsEva SA (NASDAQ: OBSV / SIX:…
Read morepress release
October 3, 2018
Phase 3 IMPLANT 2 trial results showed Live Birth Rate increased by up to 35% with Nolasiban treatment Nolasiban safety…
Read morepress release
September 28, 2018
Linzagolix overall efficacy and safety maintained or improved at week 24 Linzagolix 75mg once daily showed no clinically significant impact…
Read moreMay 8, 2019
May 9, 2018
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840